NX-5948, A Clinical-Stage BTK Degrader, Achieves Deep Suppression Of BCR, TLR, And Fcr Signaling In Immune Cells And Demonstrates Efficacy In Preclinical Models Of Arthritis And Other Inflammatory Diseases By aterrado@waterhousebrands.com / January 7, 2025
A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton’s Tyrosine Kinase Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B-Cell Malignancies By dev@sirosolutions.com / December 17, 2024
A Rapid Matrix Approach For The Discovery Of Potent IRAK4 Targeted Protein Degraders By dev@sirosolutions.com / December 17, 2024
